|Daily Range||$8.31 - $8.60|
|52-Week Range||$3.43 - $13.32|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||103,966|
|Current FY EPS||-$0.67|
Prosensa Holding B.V. (RNA) Description
Prosensa Holding B.V. Website: http://www.prosensa.eu/
Sarepta Therapeutics stock has been whipsawed over the past year. Find out what's been the cause of its volatility and whether or not the stock can head higher.
Sarepta Therapeutics is a clinical-stage biotechnology company seeking to gain approval for a potentially game-changing Duchenne muscular dystrophy drug called eteplirsen. Wall Street appears convinced that the drug is a winner, but scientists have been less optimistic. Here's why.
Should You Buy Prosensa Holding (RNA) Ahead of Earnings? - Tale of the Tape
These health-care stocks experienced a horrendous week -- with each plunging more than 20%.
Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.